Weight Loss & Metabolic
Peptides studied for fat oxidation, appetite regulation, insulin sensitivity, and body composition.
21 peptides in this category
Tesamorelin
Tesamorelin is a synthetic stabilized analog of GHRH composed of the full 44-amino acid sequence of GHRH, conjugated with a trans-3-hexenoic acid modification t...
FDA-approved (Egrifta) for HIV-associated lipodystrophy. Active research ongoingAOD-9604
AOD-9604 is a modified peptide fragment corresponding to amino acids 176-191 from the C-terminal region of human growth hormone, with a stabilizing tyrosine mod...
Has completed Phase I/II human safety trials with acceptable tolerability. InconFragment 176-191
Fragment 176-191 refers to the unmodified C-terminal peptide fragment of human growth hormone spanning amino acids 176-191. It is the precursor compound from wh...
Primarily preclinical data. Less studied than AOD-9604. Research-grade compoundKisspeptin
Kisspeptin refers to a family of peptides (KP-54, KP-14, KP-13, KP-10) encoded by the KISS1 gene, which are essential regulators of the hypothalamic-pituitary-g...
Active Phase II clinical trials for infertility and reproductive disorders. A syFollistatin-344
Follistatin-344 is a 344-amino acid isoform of the native glycoprotein follistatin, engineered for targeted research applications. Follistatin is a potent endog...
Active clinical trials as gene therapy (AAV1-FS344) for neuromuscular diseases iMOTS-c
MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame within the 12S rRNA gene of mitochondrial DNA. It is one of ...
Preclinical data primarily in mice and cell culture. Growing human observational5-Amino-1MQ
5-Amino-1MQ is a small-molecule methylquinolinium derivative that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that ...
Preclinical only (cell culture and mouse models). Growing clinical interest. NoSemaglutide
Semaglutide is an FDA-approved synthetic 31-amino acid analog of glucagon-like peptide-1 (GLP-1), modified with a C18 fatty acid chain via a linker to albumin f...
FDA-approved for T2D, obesity, and cardiovascular risk reduction. Active researcTirzepatide
Tirzepatide is an FDA-approved first-in-class dual GIP/GLP-1 receptor agonist peptide that simultaneously activates both glucose-dependent insulinotropic polype...
FDA-approved (2022 T2D, 2023 obesity). Active Phase III research in NASH, heartRetatrutide
Retatrutide is an investigational first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it has demo...
Phase III trials ongoing (7 additional Phase III readouts expected in 2026). NotLiraglutide
Liraglutide is an FDA-approved GLP-1 receptor agonist peptide with 97% structural homology to human GLP-1, modified with a fatty acid side chain enabling self-a...
FDA-approved (2010 T2D, 2014 obesity). Extensive post-marketing safety data. PriCagrilintide
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta ...
Phase III clinical trials ongoing (CagriSema for obesity and T2D). Phase II dataPramlintide
Pramlintide (brand name Symlin) is a synthetic 37-amino acid analog of human amylin with three proline substitutions that prevent the spontaneous aggregation an...
FDA-approved 2005 for T1D and T2D as insulin adjunct. Long-term safety data avaiGlucagon
Glucagon is a 29-amino acid pancreatic peptide hormone secreted by alpha cells of the islets of Langerhans in response to hypoglycemia. Its primary function is ...
FDA-approved for emergency hypoglycemia (1960). GCGR agonism as a component of cInsulin (Endogenous Peptide)
Insulin is a 51-amino acid peptide hormone produced by pancreatic beta cells, consisting of an A-chain (21 AA) and B-chain (30 AA) connected by two disulfide bo...
FDA-approved since 1982 (recombinant human insulin). Multiple analog formulationGhrelin
Ghrelin is a 28-amino acid acylated peptide hormone produced primarily by X/A-like cells of the gastric fundus. It is the endogenous ligand for the growth hormo...
Characterized 1999 (Kojima et al.). Not used therapeutically as exogenous ghreliCholecystokinin (CCK)
Cholecystokinin (CCK) is a peptide hormone found in multiple forms (CCK-8, CCK-33, CCK-58) secreted by enteroendocrine I-cells of the duodenum and jejunum in re...
Extensively characterized endogenous peptide. CCK analogs and CCK-1R agonists unPYY (Peptide YY)
Peptide YY (PYY) is a 36-amino acid gut peptide released from L-cells of the distal intestine and colon in proportion to caloric intake. The truncated form PYY(...
Endogenous peptide: extensively characterized. PYY(3-36) intranasal (NN9748): PhExendin-4 (Exenatide)
Exendin-4 is a 39-amino acid peptide originally isolated from the venom of the Gila monster lizard (Heloderma suspectum) that shares 53% sequence homology with ...
FDA-approved 2005 (Byetta, twice-daily). Extended-release formulation Bydureon (Survodutide
Survodutide (BI 456906) is an investigational dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed by Boehringer Ingelheim. Unlike ...
Phase II trials completed for obesity and NASH (2023-2024). Phase III trials iniCardarine (GW-501516)
Cardarine (GW-501516) is a PPARδ (peroxisome proliferator-activated receptor delta) agonist, not a SARM in the strict sense, but it is commonly grouped with SAR...
Clinical development discontinued by GSK in 2007 due to carcinogenicity in roden